Risk of Intracerebral Hemorrhage in Patients with Arterial Versus Cardiac Origin of Cerebral Ischemia on Aspirin or Placebo: Analysis of Individual Patient Data from 9 Trials

Stroke

Volumn 35, Issue 3, 2004, Pages 710-714

  Ariesen, M J ^a   Algra, A ^a   Koudstaal, P J ^b   Rothwell, P M ^c   Van Walraven, C ^d  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c RADCLIFFE INFIRMARY   (United Kingdom)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Cerebral ischemia; Intracerebral hemorrhage; Secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ATENOLOL; PLACEBO; WARFARIN;

ADULT; AGE; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GENDER; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONBIOLOGICAL MODEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTERIAL OCCLUSIVE DISEASES; ASPIRIN; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CAUSALITY; CEREBRAL HEMORRHAGE; COMORBIDITY; HUMANS; MULTIVARIATE ANALYSIS; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT;

EID: 1442299279     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000116868.45282.67     Document Type: Article

References (10)

1. Gorter JW. Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors: Stroke Prevention In Reversible Ischemia Trial (SPIRIT): European Atrial Fibrillation Trial (EAFT) Study Groups. Neurology. 1999;53:1319-1327.
2. Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol. 1997;42:857-865.
3. European Atrial Fibrillation Trial (EAFT) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet. 1993;342:1255-1262.
4. Dutch TIA Trial (DTT) Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med. 1991;325:1261-1266.
5. UK-TIA Study Group. The United Kingdom Transient Ischemic Attack (UK-TIA) Aspirin Trial: final results. J Neurol Neurosurg Psychiatry. 1991;54:1044-1054.
6. Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Design of a multicenter randomized trial for the Stroke Prevention in Atrial Fibrillation Study. Stroke. 1990;21:538-545.
7. Stroke Prevention in Atrial Fibrillation (SPAF) II Study. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation. Lancet. 1994;343:687-691.
8. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet. 1989;1:175-179.
9. Koefoed BG, Gullov AL, Petersen P. Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulant Therapy Study (AFASAK 2): methods and design. J Thromb Thrombolysis. 1995;2:125-130.
10. Hellemons BS, Langenberg M, Lodder J, Vermeer F, Schouten HJ, Lemmens TG, et al. Primary prevention of arterial thromboembolism in nonrheumatic atrial fibrillation: the PATAF trial study design. Control Clin Trials. 1999;20:386-393.